SEARCH

SEARCH BY CITATION

References

  • 1
    Lewis R, Dixon J. Rethinking management of chronic diseases. BMJ 2004; 328: 2202.
  • 2
    Basilakis J, Lovell NH, Celler BG. A decision support architecture for telecare patient management of chronic and complex disease. Med J Aust 2007; 179: 2426.
  • 3
    Celler BG, Lovell NH, Basilakis J. Using information technology to improve the management of chronic disease. Med J Aust 2003; 179: 2426.
  • 4
    Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 11925.
  • 5
    Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J. Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. Pharmacotherapy 2005; 25: 2659.
  • 6
    Terry K. Monitor patients on-line? Med Econ 2001; 78: 6770.
  • 7
    Baker AM, Lafata JE, Ward RE, Whitehouse F, Divine G. A web-based diabetes care management support system. Jt Comm J Qual Improv 2001; 27: 17990.
  • 8
    O’Shea S, Arcasoy M, Samsa G, Cummings S, Thames E, Surwit R, Ortel T. Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J Thromb Thrombolysis 2007; 26: 1421.
  • 9
    Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 198791.
  • 10
    Rosendaal FR, Cannegieter SC, Van Der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 2369.
  • 11
    Ryan F, O’Shea S, Byrne S. The reliability of point-of-care prothrombin time testing. A comparison of CoaguChek S® and XS® INR measurements with hospital laboratory monitoring. Int J Lab Hematol 2008; DOI: DOI: 10.1111/j.1751-553X.2008.01120.x.
  • 12
    Oake N, Fergusson DA, Forster AJ, Van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Can Med Assoc J 2007; 176: 158994.
  • 13
    White HD, Gruber M, Feyzi J, Kaatz S, Tse H-F, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 23945.
  • 14
    Van Walraven C, Oake N, Wells PS, Forster AJ. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromobembolic events in the elderly. Chest 2007; 131: 150815.
  • 15
    Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol 2005; 132: 27785.
  • 16
    Palareti G, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Leali N, Poggi M, Legnani C, Musolesi S, Coccheri S. Thrombotic events during oral anticoagulant treatment: results of the inception, prospective, colloborative ISCOAT study: ISCOAT study group (Italian Study on complications of Orla Anticoagulant Therapy). J Thromb Haemost 1997; 78: 143843.
  • 17
    Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000; 9: 28392.
  • 18
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 6(suppl): 160S98S.
  • 19
    Piso B, Jimenz-Boj E, Krinninger B, Watzke HH. The quality of oral anticoagulation before, during and after a period of patient self-management. Thromb Res 2002; 106: 1014.
  • 20
    Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893900.